Abbvie, Author Interviews, Rheumatology / 27.11.2019
Upadacitinib for Rheumatic Condition Ankylosing Spondylitis
MedicalResearch.com Interview with:
[caption id="attachment_52304" align="alignleft" width="200"] Dr. Pangan[/caption]
Aileen Lorenzo Pangan MD
Executive Medical Director
AbbVie
MedicalResearch.com: What is the background for this study?
Response: Our ongoing commitment to advancing the standard of care for patients with rheumatic diseases is illustrated by our growing portfolio and the thirty-eight abstracts we presented at this year's ACR/ARP Annual Meeting, including results from five studies of RINVOQ in rheumatoid arthritis (RA) and primary results from our study in ankylosing spondylitis (AS).
Dr. Pangan[/caption]
Aileen Lorenzo Pangan MD
Executive Medical Director
AbbVie
MedicalResearch.com: What is the background for this study?
Response: Our ongoing commitment to advancing the standard of care for patients with rheumatic diseases is illustrated by our growing portfolio and the thirty-eight abstracts we presented at this year's ACR/ARP Annual Meeting, including results from five studies of RINVOQ in rheumatoid arthritis (RA) and primary results from our study in ankylosing spondylitis (AS).